RSS
 

Posts Tagged ‘lindsay rosenwald’

History of Paramount

11 Jun

Paramount BioSciences, LLC (“Paramount”) is a leading pharmaceutical development and investment company with its main focus on the biotechnology and life sciences sectors. With Paramount BioCapital, Inc., a FINRA registered broker-dealer in head of funding and raising capital for Portfolio companies, Paramount BioSciences heavily contributes to the emergence and development of innovative biotechnologies and life sciences.

Paramount BioScienses’ Model

Not only does Paramount BioSciences provide technical services and support, but is also engaged in new product development, biotech companies acquisition and development. It supports the newly created companies in several value-adding ways. They evaluate product candidates for the Portfolio companies, create development plans to facilitated the development process before, during, and after the formation of Portfolio Companies. Both, back-up and expertise is fully supported by BioSciences as it allows its Portfolio Companies to access to much more experienced infrastructure than they might have. This allows the company management to focus on the drug candidates’ development rather than building their own infrastructure. In many ways, this model developed by Paramount’s founder Lindsay Rosenwald provides both professional and “back office” support and limits delays in the development process, as well as maximized the returns for Portfolio companies and the patient community.

After approval and in-licensing, drug candidates are managed by a dedicated management team through the whole development cycle. Senior drug development staff at Paramount BioSciences, including Lindsay Rosenwald, supports Portfolio Companies in all aspects of pharmaceutical development. This includes formulation, clinical development, toxicology, manufacturing, quality assurance, and commercialization. With their extensive experience in developing leading pharmaceutical products, the Paramount’s team provides solutions for a variety therapeutical indications, starting from inflammation to cardiovascular to oncology to neurology and many other indications. Global network of consultants as well as industry leaders in the medical and scientific communities provide help during the candidates’ development and approval cycle.

With a proven track record, Paramount BioSciences helps Portfolio Companies recruit executives that will lead the new companies formed around the new compounds. Among the recent hires at Portfolio Companies, there are such executives as the former CEOs of Roche, Biogen, Sanofi-Aventis, Johnson&Johnson, Amgen and many others.

Over 20 years of financing and development of biomedical companies across a broad range of therapeutic indications, Lindsay Rosenwald in head of Paramount BioSciences nurtured more than 40 biotech companies. He builds companies from the ground up utilizing its own capital and then funds are raised from various private investors through Paramount Capital.

Paramount handles such important functions as accounting, legal, market analytical, financial functions. This helps its Portfolio companies focus on clinical studies and creating value for shareholders, licensors and patients.

With such a keen eye for finding and developing innovative drugs, Paramount BioSciences evaluates the quality and promises of drug candidates throughout the world, from small biotech firms and academic centers to large pharmaceutical corporations.

Paramount Process To Value Creation

What stands Paramount BioSciences out, is that their infrastructure and external network allows them to support Paramount Incubated Companies until they become self-sufficient. The development cycle has been developed by Lindsay Rosenwald in 1999 and can be described in a simple scheme similar to this one:

Product Assets à Paramount Initial Financing and Development àIncubation àPortfolio Company Formation à Value Inflection Point

Employees for each Portfolio Company are hired in accordance with developmental and financial circumstances. On average, most employees at Paramount have at least 15 years of experience in biotechnology or medical care sectors driving drug candidates through the regulatory and clinical value chain. Their expertize ranges from molecular biology to clinical medicine.

With such a deep experience across the drug development business, Lindsay Rosenwald has managed to build the team with leadership roles in the biotech market authorizations of numerous pharmaceutical products being sold worldwide, including Viracept, Neulasta, Rituxan, and Kepivance.

Paramount Business Units

Paramount Biosciences

With over 40 employees in 8 offices globally, Paramount BioSciences assess and negotiate for university and corporate biotechnology licenses. It develops and in-licenses compounds for various therapeutic indications – from inflammation and cardiology to neurology and cancer. Lindsay Rosenwald helps build standalone biotech companies that can attract capital and succeed as public companies

Paramount BioCapital, Inc.

Paramount BioCapital Inc. is a NASD-registered dealer that raises capital for the Portfolio Companies. It raised more than $1 billion and approximately $200 million in 2009. With their extensive expertise in securities transactions such as “PIPEs”, reverse mergers, self-registrations and private placements, Paramount BioCapital has become the leader in the biotechnology capital sector.

Paramount Corporate Development

Lindsay Rosenwald works closely with Paramount Corporate Development, which is involved in in-licensing and drug development activities. The Corporate Development group comprises of 20 industry veterans with a huge experience in all aspects of pharmaceutical development, including formulation, clinical operations, manufacturing and commercialization.

Paramount BioCapital Asset Management

Asset Management is responsible for purchasing and distributing equities of global healthcare companies. It has a proven hedge fund structure and assets under management in various private placement vehicles.

Paramount Acquisition Company

Paramount Acquisition Company creates unique private equity vehicles that match large capitals with late-stage private companies. It recently announced a $54 million transaction with Valeritas, which is a medical device company with its main FDA-approved insulin pump h-Patch.

Paramount BioSciences Executive Leadership Team

On average, Paramount BioSciences employees have 15 years of direct experience in the clinical and regulatory processes. Headed by Lindsay Rosenwald, the team members participated in dozens of pharmaceutical development and commercialization projects, including Rituxan, Viracept, Sutent, Kepivance, and Neulasta. More than 50 compounds currently undergo clinical development process and the products include drugs across a wide range of indications that include neurological disorders, metabolic conditions, infectious diseases and cancer.

Lindsay A. Rosenwald, M.D., is CEO and Chairman at Paramount BioSciences. His extensive experience in biotechnology, pharmacology and finance made him one of the leaders in the biotechnology and life sciences sectors. With more than 20 years of experience in developing and investing in biotechnology and life science companies, Dr. Lindsay Rosenwald founded and nurtured more than 40 biotech/pharma companies.

J. Jay Lobell, J.D., is President and Chief Operating Officer at Paramount BioSciences. His previous experience includes partnership at Covington & Burling, where he provided financial, regulatory, business, and litigation advice to financial institutions, corporations and individuals.

Russell Ellison, M.D., is Executive Vice President with over 30 years of senior management experience in pharmaceutical development and commercialization. He is a former Vice President Clinical Development at Fibrogen, Inc. and Chief Medical Officer of Sanofi-Synthelabo, USA. Dr. Ellison also served as the U.S. Vice President of Medical Affairs and is a former U.S. Vice President, Medical Affairs and Chief Medical Officer of Hoffman La Roche.

Advantages of Paramount BioSciences Model

What makes Paramount BioSciences a preferred acquirer of drugs and developer of biotechnologies is that Lindsay Rosenwald’s development team works with a global business development group that assesses and facilitates product and market opportunities. The offices of Paramount BioSciences are located worldwide, including New York City, London, Boston, Shanghai, San Diego, North Carolina, Orange County (California)). Promising drug candidates are moved forward quickly in the licensing process. Representatives of all areas in drug development cycle work together to ensure an agreement to move forward. The next step is the creation of product development plans for the compound and hiring management staff. At this stage, the compounds are transferred to Portfolio Companies with no transitional delay. The product candidates are supported through the clinical and regulatory process.

Paramount BioSciences has proved to rapidly execute deals and begin development work. Its access to the capital is an important part of any product development. It provides Portfolio companies with the structure that promotes drug candidate’s progression through to market, eliminating chances of program being shelved.

Clinical and commercial expertise at the company level helps Paramount Portfolio companies maximize value to in-licensed products.

History of Financial Wherewithal

Paramount BioSciences under the leadership of Lindsay Rosenwald has risen over $1 billion from outside investors in addition to their own investment in Paramount’s portfolio companies. All companies and clinical studies funded by the company receive substantial financing on all stages of the development cycle.

Lindsay Rosenwald has regular and close interaction with the leading US sell-side and buy-side institutions that include notable medical care investors, with whom Paramount’s hedge funds invest in the deals not directly involving the company itself. Paramount’s employees have real-time understanding of healthcare capital markets, which resulted in over $400 million funds for Portfolio Companies in 2009 year alone, including $200 million by Paramount. This includes $47 million for Cougar Biosciences in conjunction with SG Cowen, $37 million for Ziopharm Oncology, $22 MM for Chelsea Therapeutics and $16 million for Innovive Pharmaceuticals. Many of the premier healthcare funds financed in Paramount this year, which remains a good sign for the development of biotechnology and life sciences sectors.

 
No Comments

Posted in Lindsay Biotechnology

 

Achievements Of Dr. Lindsay Rosenwald Serve As A Source Of Inspiration For The Youth

10 Jun

Establishment of Paramount Bio Capital by Dr. Lindsay Rosenwald in 1991 has led him to the achievements in the field of bio technology and medical research. This company soon emerged as basis for the development of other portfolio companies of Paramount group of companies. Rosenwald is also the founder chairman for all the portfolio companies of the Paramount group. There are many achievements made by Rosenwald and his group of companies and they are one of the most trusted and most famous companies in the market.

There are many portfolio companies the Paramount group and some of them are involved in the drug research. There is a separate company named as Paramount Corporate Development which is intended for the co-ordination and facilitation of drug development and drug research in these companies, which are founded by Dr. Lindsay Rosenwald. Also, Paramount Corporate Development is involved in the general corporate development of the portfolio companies of the group.  Another one in the group of Paramount companies is Paramount Bio Sciences. It is a multi national company. This health care investment company concentrates on the concepts that produce new drugs and also the companies which try to produce them. The main of this company is to provide support to these sprouting new companies. Paramount Bio Capital is the one that concentrates       on the capital and financial aspects of Paramount group of companies. It is crucial in finding the financial support to the portfolio companies of Paramount group. Bio Capital is a broker dealer company that has a valid registration. It is registered with Financial Industry Regulatory Authority which is usually abbreviated as FINRA. The success of Bio Capital Company can be known by looking at the statistics of the company and the fund raised by the company. Till now, the company has raised a whooping amount of nine hundred and fifty million dollars for the development of portfolio companies of the Paramount group. All these companies are initiated by Rosenwald. When coming to the life story of Rosenwald, he has done his schooling in Pennsylvania till the year 1973. Then he wanted to join in finance course at masters’ level. So, he moved to Pennsylvania State University. He has completed his graduation in Beta Sigma Gamma in the year 1977. Then he took up medicine studies at Temple University’s school of medicine. After completing his medicine studies in 1983 he joined his internship in Abington Medical Hospital. At the same time, he has started his own practice.

Lindsay Rosenwald has a passion towards finance field and it has led him to move to Wall Street. There he emerged in to a unique person by taking two professions at the same time. They are medical practitioner and analyst.  It is a unique kind of job where he is the first of his kind. Rosenwald got fame in both the professions and he is considered as legend in associating bio technology and life sciences with financial world. His initiations has now seen in the form of bigger companies which are considered as pioneer in their respective fields.

 
No Comments

Posted in Lindsay Biotechnology

 

Lindsay Rosenwald Accomplishments

22 May

Immediately after going to Abington High School, Dr. Rosenwald began his health care training at PSU in 1973. He had a fascination with exactly how businesses worked and spent a fair amount of time learning about the financial features of their operation.     

In pursuit of his lifelong wish, Lindsay Rosenwald entered Temple University’s University of Medicine. After graduating from Temple University in 1983, he began an internship at Abington Hospital before beginning his own private practice. After filling out his internship, he functioned as a medical professional in his private practice for 2.5 years. Though he liked practicing medicine Dr. Rosenwald sensed as if something was absent. He made the decision he needed to combine his 2 interests, business enterprise and medical science, and look for a career that would let him pursue those passions.

Lindsay Rosenwald eventually left his private practice in 1986 to go to Wall Street where he got on a position as a Physician / Analyst, an extremely exclusive placement with just a few people doing it at that time. In spite of the belief that doctors don’t make good investors, Dr Rosenwald excelled at this job. He worked here because he felt it was vital to focus on opportunities in the medicine and health sector. He received superb respect in his brand new position, and although he missed his old private practice, he knew this is where he truly belonged. He also worked for an exclusive investment company, DH Blair Co as the Controlling Director of Finance, but left after a few years to concentrate on a brand new enterprise.

In 1991, Lindsay Rosenwald created Paramount Biotech. With time, he has widened this company by establishing new companies and gaining control of other biotech firms. The business has financed more than two dozen businesses in the last three years. He is able to make these acquired companies successful because he focuses on both improving the corporate framework of the organization, in addition to improving the research part.. Paramount Capital is a conglomerate of firms including: Paramount biosciences,Paramount Corporate Development and Paramount BioCapital. All of these companies are separate entities, but interact to aid each other. The businesses that Rosenwald handles have licensed or obtained over a hundred experimental stage medicines.

Possibly one of Dr Rosenwald’s greatest accomplishments is that he set the record for the fastest development of a drug. In only thirty months, Arsenic Trioxide was developed and approved by the FDA for treating a deadly type of the leukemia disease. This medicine has been on the market worldwide for more than ten years and it has saved and extended 1000s of lives.

Rosenwald has been revolutionary with the firms he has created. One of his businesses sold to J&J for over One Billion Dollars despite the fact that they only had one medicine with phase 2 data. He is also the cause of bringing a stem cell business, a cancer vaccine organization, and a gene therapy company all to market. As Rosenwald as the leader, his companies have created many of the most valuable and groundbreaking drugs of the 21st century. To add to his achievements he created the first successful medicine to assist those who are obese.

One of the reasons that Rosenwald’s companies have been profitable is he employs PHDs, MDs, MBAs, and other experts to function as his senior level professionals. These people provide plenty of experience in both the medical and business arenas that will help make his businesses more powerful and more diverse. They are driven to create new medicines as fast as possible. A few of these drugs have the potential to alter the way we view medical care entirely today. He has also created the Rosenwald Foundation that has contributed millions of dollars to medical and science instruction to help create the future of medicine.

Lots of people credit the success of the biotech industry on a whole to Dr. Lindsay Rosenwald. His visionary companies have altered many lives and made Dr. Rosenwald’s personal assets soar to the tune of $600 million.

 
No Comments

Posted in lindsay rosenwald

 

Lindsay Rosenwald – His Financial Portfolio

06 May

Dr. Lindsay Rosenwald is the most well known venture capital investor in the market. He looks after a wide range of financial portfolio, which includes hedge fund, investment banking and venture capital.  Lindsay Rosenwald started a lot of companies to change the status quo in the Biotechnology market. With the experience of 20 years in handling financial portfolio, he invested in a lot of small companies and new ventures as he believes that small companies can make the impact in the market. Rosenwald received a Finance Degree from Pennsylvania University. Then he moved to Templeton School of Medicine to receive the medical degree in 1983. With the finance degree and medicine degree, he started his own medical practice and ran it for two years successfully before moving to Wall Street, New York. Once he moved to New York, he started concentrating on the advanced research on Biotechnology and started several numbers of companies. He is the founder and chairman of Paramount Group Companies. All most all the group companies of Paramount are involved in either fund raising and investing or research and development. The paramount BioCapital is one of the sister concerns of Paramount group and it is actively involved in fun raising. As per the recent news, Paramount BioCapital has raised nearly one billion dollars since its inception.

He is also the founder of various companies include Biocryst Pharmaceuticals, Titan Pharmaceuticals, Cypress Biosciences, Keryx Biopharmaceuticals, Javelin Pharmaceuticals, Polarx; and Enzymed Corp. Most of these companies are involved in drug development and advanced clinical research. In addition to this, he is one of the advisory members of advisory board of Columbia-Presbyterian Health Sciences and Advisory Counsel, which is a group that felicitates people who have done extensive research in the biotechnology industry. Dr. Lindsay Rosenwald has been serving as one of the director of several public and private limited companies around the world. The famous company, Cougar Biotechnologies has bee sold out to Johnson and Johnson for a whooping price of nearly one billion dollars. This is one of the best deals in the biotechnology market. Most of the drugs developed by Paramount Group companies get the FDA approvals with in a short span of time. All these companies have been growing at good rate under the dynamic leadership of Rosenwald.

 
3 Comments

Posted in lindsay rosenwald

 

Lindsay Rosenwald Online Mentions

05 May

MSN Money & Lindsay Rosenwald

In an online article that was posted on the MSN Money page, in the Investing section, Michael Brush describes the best way to achieve success with your investing. In 4 Picks From All-Star Insiders, Michael tells his readers about how the best way for an individual investor, such as Lindsay Rosenwald, to make money in the market is to find, follow, and mimic the most successful insiders. He also states that some insiders are better than others at knowing how to successfully navigate within the stock market game. He then goes on to name some of the top players who have some of the best stats and success in generating dollars from their investing activities.

Among the people he names as a big winner, he presents Dr. Lindsay Rosenwald as the absolute best of them all. Dr. Rosenwald has made large sums of money while operating as a hedge fund manager and venture capitalist who is based in New York. Michael Brush is quick to tell of how Lindsay Rosenwald was able to amass large profits ranging from  100% to 280%. This was done over done over the course of a six month period, after the well timed purchase of two biotech companies named Cell Therapeutics and Neose Technologies. In addition to that the average gain for each trade he made in the stocks of these two companies is 59% for Cell Therapeutics and 64% for Neose Technologies.

As stated by Michael Brush in this article, Lindsay Rosenwald has developed a great reputation as a person who really knows how to spot a winning trade. Lon Gerber, who happens to be an insider expert for Thomson Financial, says that Dr. Rosenwald’s returns are incredible. Furthermore, as far as the consistency of his success, Lindsay Rosenwald has managed to create a broad record of creating successful biotech investments over the course of several years.

New York Times Article

In the online article titled BUSINESS PEOPLE; D.H. Blair Picks Doctor As Director of Finance, Daniel F. Cuff of The New York Times describes Dr. Lindsay Rosenwald as one of the few exceptions to the Wall Street truisms which states that doctors tend to make for bad investors. This is made evident with his appointment as managing director in corporate finance for a Wall Street firm named D.H. Blair & Company.

The article then goes on to tell about Dr. Rosenwald’s earlier life and past history. Lindsay Rosenwald, who is originally a native of Philadelphia, was very conflicted as to what career he should choose. He had already finished college and attained a degree in Finance from Penn State, but he also had a strong interest in the medical field and desired to practice as a doctor. This is the reason why he soon chose to enroll in Temple University’s school of medicine.

Even during the time of his medical training and practice, he still made use of his financial knowledge and skills by managing money for his professors and various physicians. He also did some consultation work for health-care companies. Finally, even after having establishing his own medical practice, Dr. Rosenwald decided to give in to the call of Wall Street that was again urging him to pursue work in the financial world.

Daniel F. Cuff then explains how Lindsay Rosenwald combined his knowledge of finance and medicine in order to gain a unique edge when dealing with financial markets. Dr. Rosenwald went to New York in order to work as a securities analyst. Eventually, he got married and started a family, settling down in Manhattan. He also began spending his time looking for and investing in start-up biotech companies that have the potential to make money. The companies he has worked with include names such as Molecular Biosystems, Organogenesis and Marrow Tech.

Cougar Biotech Blog

Cougar Biotech – Wow! is an article that was written by David Feldman and deals with a topic related to finance. Specifically, it talks about a man named Dr. Lindsay Rosenwald and the company named Cougar Biotechnology. David Feldman starts out by highlighting the successful selling of Cougar Biotechnology to Johnson & Johnson for an offer of $1 billion. He also notes that Cougar Biotechnology is backed by none other than Dr. Lindsay Rosenwald himself. David also tells of how Cougar Biotechnology reverse merged with a Form 10 shell that was affiliated by Richard Rappaport’s WestPark Capital in LA, back in 2006.

David Feldman says that the stock price of Cougar Biotechnology rose by 145% since the time when it began to trade after the very beneficial reverse merger. The pre-arranged financing of Cougar Biotechnology was set at an incredibly high dollar amount for its time and even for now today. This totaled 50 million and took place during the time of the reverse merger. The article goes on to state that this reverse merger of a company backed by Dr. Rosenwald can be put on the list of the most successful reverse mergers ever. He also compares the success of the merger to others such as Texas Instruments, Blockbuster Entertainment, Berkshire Hathaway, Occidental Petroleum, Tandy Corp. (Radio Shack), and Turner Broadcasting just to name a few.

Below this article, a comment from a reader, made on February 7, 2010, goes on to explain some of the other accomplishments of Dr. Lindsay Rosenwald. Namely, stating how his various contributions to the world of medical research and the biomedicine field has been of a huge benefit to many. Jake Wilson then states that Dr. Rosenwald’s contributions mainly originate from the group of companies for which the doctor himself is the Founder and Chairman, Paramount. After that there is mention of how the Paramount companies are actively involved in things such as facilitating and coordinating research, corporate development, global investing and development, and the support of biotech companies that are new to the arena business.

Temple Times & Lindsay Rosenwald

Giselle Zayon has created a rather informative article for the online edition of Temple Times. The title of that article is Dual degree helps Medical School graduates take on business world and it speaks about how Dr. Lindsay Rosenwald, a trained medical doctor as well as a financial guru, has combined both his knowledge and unique talents in order to operate as a strong force in the financial world. Giselle describes Lindsay Rosenwald as definitely being the person you want to see if you wish to learn more about biotechnologies and emerging drugs, even if the doctor no longer chooses to practice as a medical physician.

Also noted in the article is Dr. Rosenwald’s work with the Paramount Capital group of companies. As stated in the article, Lindsay Rosenwald is the original founder and now operates as Chairman to this group. Paramount Capital is a very successful organization that specializes in various activities such as direct investing investment banking and venture capital in the life-sciences and biotechnology industries, asset management. All of this being done from various offices spread throughout the world, across a total of three continents.

Dr. Rosenwald seems to be a man that was born to make money and be a key player in the financial world. In the article, Giselle Zayon goes on to quote Dr. Lindsay Rosenwald telling of how he manages investor assets, works with private equity, both offshore and domestic hedge funds, invests in both public and private turnaround and start-up companies, and makes placement offerings for certain biotech companies.

The doctor originally studied and attained a degree for finance and economics at Penn State University before taking up medical studies at Temple. A short time after also completing his medical school training, internship, and even establishing his own practice, Lindsay Rosenwald decided to return to the world of finances.

 
1 Comment

Posted in lindsay rosenwald

 

Dr. Lindsay Rosenwald- A Leader of Drug Development

02 May

Dr. Lindsay Rosenwald is said to be one of the founder of Biotechnology and also to the science dealing with human life. He has put a lot of efforts to the development of these fields and helped many of the young researchers to go on with their innovative ideas. There are many companies started by him and these are the companies which made the fields of medical reach such heights. Rosenwald’s companies have recruited many of the new researchers.

Under Rosenwald’s foundation Paramount BioSciences is one which develops the Biotechnology field and increases the investment bank. This is the organization under which numbers of researchers grouped into teams strived hard to start a company and were successful by reaching to certain low height. Though this is a small measure was good at its initial stages.

Paramount BioSciences is also included in the global hunt of the new companies under various fields of Biotechnology and ensures them that it withstands with the company in its researches and helps in financial matters in combination with Paramount BioCapital. This organization also ensures these companies that it helps them to provide the results within their schedule and as soon as they complete their researchers they are taken with care to improve their further researchers. This organization Paramount BioSciences also encourages these companies to reach their objectives and goals more effectively and efficiently.

The teams help the companies to handle the drug development. The team mainly is formed by the members like managing directors, Ph Ds, legal representatives, accounts, drug developers and many more who are highly qualified according to their positions in the companies who are authorized by their superiors and are given by the objectives to fulfill their jobs to make the company reach the goals.

Paramount BioCapital founded in nineteen ninety one is a part of Rosenwald’s entrepreneurship as a start. Silhouette of Dr. Lindsay Rosenwald includes general practitioner and economic analysis which was one of the difficult tasks to be taken into control by few people who are mastered in these issues. This helps Rosenwald to launch few more companies which are related to the fields of Biotechnology and Life Sciences.

Dr. Lindsay Rosenwald done his education from Pennsylvania and obtained graduation from schooling in the year nineteen seventy three. He then joined Abington High School to study and then after that joined Pennsylvania State University to complete his course related to Finance and Economy. Where he become chief in these fields in the year nineteen seventy seven and was tribute with Beta Gamma Sigma. He worked has a specialist for few years in the healthcare corporations and then went to Temple University’s School of Medicine in the year nineteen eighty three to complete his medicine.

Dr. Lindsay Rosenwald practiced his initial private enterprise scheme when he declared to be eligible to perform as a physician. He then moved to New York after practicing there for few more years and dedicating to many of the fields in various forms. All his dedications were to the development and improvements to the fields of Biotechnology.

 
1 Comment

Posted in Lindsay Biotechnology

 

More About Lindsay Rosenwald

20 Apr

As the founder and chairman of Paramount Capital, Dr. Lindsay A Rosenwald, performs jobs with that unit of businesses which is mostly concerning investment money managing, asset supervision, plus direct investing and venture capital in life-science and biotechnological industries. The Paramount Capital Asset Management organization utilizes a amalgamation of domestic and also foreign hedge funds and also private equity for the purpose of managing their investor assets. Paramount Capital is a dealer who has FINRA membership and they are experts in serving public and private biotechnology companies in the development stage in supervising private and public placement offerings. The Paramount Capital Investments, LLC group is a venture capital group whose effort is to take a securing interest in both private and public establishments. This includes failing turn-around and start-up businesses. Paramount BioSciences is both a healthcare investment bank and an internationally run pharmaceutical item enhancement firm. Additional to that Dr. Lindsay Rosenwald has obtained a membership with the Managing Member of Orion Biomedical Fund, LP and the Orion Biomedical Offshore Fund, LP. Both of these parties are managing in Financing. During 20 years time, Dr. Lindsay Rosenwald has operated as a Wall Street capitalist in biotechnology. He has created and re-capitalized dozens of private and public life-sciences and biotechnology companies. The portfolio establishments of Paramount have so far manufactured three new chemical agents that have been approved by the FDA and they at the current moment have a large number of products that are as of now undergoing clinical trials. Among these is a portfolio company called PolaRx BioPharmaceuticals, Inc., has been awarded a final marketing consent for a leukemia product accepted as arsenic trioxide. This was accomplished only 30 months, an industry best, after the therapy of the actual first testees was completed in a corporate clinical assessment. 5 Other than Cougar Biotechnology, Dr. Lindsay Rosenwald has as well taken it upon himself to both support or establish such companies as Bradley Pharmaceuticals, Inc., Repligen Corporation, Avigen, Inc., Cardiome Pharma Corp., Neose Technologies Inc., Biocryst Pharmaceuticals, Inc, Cypress Bioscience, Inc., Genta, Inc, Discovery Laboratories, Inc., Indevus Pharmaceuticals, Inc., Keryx Biopharmaceuticals, Inc., Cell Therapeutics, Inc., and Hudson Health Sciences, Inc.

In relation to his educational background, Dr. Lindsay Rosenwald became a graduate from Abington High School, in the southeast region of Pennsylvania, back in 1973. The future doctor and business man went on to graduate Beta Gamma Sigma as well as a degree in Finance and Economy from Pennsylvania State University in 1977. Shortly after, he landed employment as an independent management consultant, laboring for various health care businesses during the years 1977 to 1979 and then enrolling himself into the Temple University School of Medicine. He graduated from Temple in 1983 and soon afterward took up an internship at the Abington Medical Hospital, staying in the private medical system until the year 1986. Dr. Lindsay Rosenwald then moved on to Wall Street in order to join his financial and medical skills and manage as a doctor/financial analyst.

Lindsay’s Career Path

Dr. Lindsay A. Rosenwald presented himself as a corporate finance managing director for D.H. Blair & Company, during 1988. This was a non public investor business. There, he was the person in charge of a team of three doctors of medicine-financiers that hunted through the health community for any new and viable inventions that could make use of private investment. They located various medical schools, universities, hospitals, drug companies, research groups, and scientific firms. Dr. Lindsay Rosenwald then managed to start Paramount BioCapital in 1991. Here, he dealt within the biotechnology and bioresearch domains. He was made a NASD-member dealer in 1992 and founded the investment and merchant bank named Paramount Capital Investments LLC, in 1995. Owned by Dr. Lindsay A. Rosenwald, the Paramount Capital Asset Management company has controlled investments from quite a few funds since 1994 that are specialized in the biotechnology and other technological sectors. Dr. Rosenwald serves on the Columbia-Presbyterian Health Sciences Advisory Counsel and in the 2002 article edition of Genetic Engineering News he was ranked number one in the list of 100 Molecular Millionaires possessing a worth of $617,721,671. Dr. Lindsay Rosenwald worked on the Keryx Biopharmaceutical, Inc board of directors from 2002 to 2006. He resigned in order to contribute extra time laboring in the biotechnology area. Cougar Biotechnology, purchased by Johnson & Johnson in 2009, is another establishment that was first founded by Dr. Rosenwald and was based exclusively on abiraterone acetate. Abiraterone Acetate, even though it had not yet arrived at phase III in clinical testing trials, was showing so much potential in the therapy and curing  for prostate cancer that Johnson & Johnson made a short-term unification bid and procurement  for the Cougar Biotechnology establishment for $1 billion. Dr. Lindsay Rosenwald, apart from the various ventures which have offered backing and capital to portfolio companies, has also established the Rosenwald Foundation. This is a nonprofit outfit that has been triumphant in securing millions of dollars in endorsement of various medical and scientific teaching institutions.

 
No Comments

Posted in Lindsay Biotechnology

 

Paramount Biosciences Profile

05 Mar

Dr. Lindsay A. Rosenwald established Paramount BioSciences, a transnational pharmaceutics developer and health & sciences funding business, in 1991.  Paramount backs the growth of drugs and therapies, keeping a firm dedication to the latest therapies and medicinal drugs demonstrating high potential.  Through the assessment of high-potential pharmaceutic prospects throughout the globe, Paramount has created, fostered, and supported over 40 science companies, academia and learning centers, and biotech & pharmaceutical companies for almost 2 decades, 20 of them spanning the last 4 years exclusively.  Paramount’s existent Portfolio Companies now hold over 40 possible products moving through clinical tests.

Lindsay Rosenwald’s Paramount Group of Companies have assumed an extremely singular approach to biotechnology funding.  Paramount BioCapital is a registered broker-dealer with FINRA, and renders funding and financial support for the  Paramount Portfolio Companies.  So far, Paramount BioCapital has rendered over $1 billion for the Portfolio Companies.  A great deal more has been generated for the group by other means.  These types of risk capital and private equity establishments are commonly investment-oriented; Lindsay Rosenwald’s Paramount Group concentrates on procedures, setting up young companies from the base up.  This procedure commences with Paramount’s own funding.  In time, funding changes over to finances yielded privately and via institutional backers.  Paramount has a firm background in finance and business, which facilitates the presentation of the operational model as viable to prospective licensors and chief executive officers.

Although Paramount Capital chiefly centers on accounting, finances, and market analysis/legalities, particular directors of separate Portfolio firms are free to drive possible treatments through the clinic, returning value for investors, licensors, and patients.

Lindsay Rosenwald has carefully formatted Paramount’s logistics to assure a hard support organization, applying knowledge and background in licensing, exploration, and evolution, corporate structure and logistic procedures, and regulative issues.  Every new Portfolio Company is based around the latest science, research, and revenue potentiality.  These firms are handled by Paramount through a concentrated top-line management at the corporate level, and also through business and clinical development and logistics experts utilized by Paramount in New York.  For example, Dr. Lindsay Rosenwald also launched Chelsea Therapeutics based on an advanced anti-folate under development for the aim of caring for inflammatory diseases, including rheumatoid arthritis and psoriasis.  This treatment has displayed promise in relation to* safety and potency against Methotrexate, which is presently the treatment preference for RA.  Methotrexate is considered to increment the levels of liver enzymes in a multitude of subjects.  Through Paramount Capital, Lindsay Rosenwald licensed this progression via South Alabama University, and assembled a skilled management group to aid in the maximization of the potentiality of this substance, and also to as drive forth the development of this and additional compounds.

Also licensed by Paramount is a collection of organic arsenic trioxide compounds through the MD Anderson Cancer Center.  This treatment, sanctioned by the Food and Drug Administration, proceeded from IND to NDA in fewer than 3 years.  This is the fastest approval process in the Administration’s history.  Likewise of note is Tisenox, a nonorganic variation of arsenic trioxide, which has exhibited a tendency to bring about cardiac deviances at larger doses. Tisonex, even at 20 times above the conventional dose, exhibits no evidence of demonstrating these issues.   Therefore, Lindsay Rosenwald founded Ziopharm Oncology for the aim of formulating this treatment for its applications in cancer treatment.  Ziopharm is now formulating additional cancer compounds as well.  Lindsay Rosenwald also initiated Keryx Biopharmaceuticals for the research of Sulonex, an oral compound for diabetic kidney disease.  Alfa Wassermann, an Italian private pharmaceutical company has licensed this compound.  If successful. Sulonex will be useable for the treatment of 15 million individuals who suffer with Type 2 diabetes and 1 to 2 million with diabetes Type 1.

 
No Comments

Posted in Lindsay Biotechnology